Acrivon Therapeutics, Common Stock Buy Hold or Sell Recommendation
| ACRV Stock | 7.52 0.17 2.31% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Acrivon Therapeutics, Common is 'Cautious Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Acrivon Therapeutics, Common given historical horizon and risk tolerance towards Acrivon Therapeutics,. When Macroaxis issues a 'buy' or 'sell' recommendation for Acrivon Therapeutics, Common, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Acrivon Therapeutics, Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Acrivon and provide practical buy, sell, or hold advice based on investors' constraints. Acrivon Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Acrivon |
Execute Acrivon Therapeutics, Buy or Sell Advice
The Acrivon recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Acrivon Therapeutics, Common. Macroaxis does not own or have any residual interests in Acrivon Therapeutics, Common or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Acrivon Therapeutics,'s advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Acrivon Therapeutics, Trading Alerts and Improvement Suggestions
| Acrivon Therapeutics, generated a negative expected return over the last 90 days | |
| Acrivon Therapeutics, has high historical volatility and very poor performance | |
| Net Loss for the year was (60.39 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Acrivon Therapeutics, generates negative cash flow from operations | |
| Acrivon Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| Over 76.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 19910 shares by Blume-jensen Peter of Acrivon Therapeutics, at 6.44 subject to Rule 16b-3 |
Acrivon Therapeutics, Returns Distribution Density
The distribution of Acrivon Therapeutics,'s historical returns is an attempt to chart the uncertainty of Acrivon Therapeutics,'s future price movements. The chart of the probability distribution of Acrivon Therapeutics, daily returns describes the distribution of returns around its average expected value. We use Acrivon Therapeutics, Common price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Acrivon Therapeutics, returns is essential to provide solid investment advice for Acrivon Therapeutics,.
| Mean Return | -0.21 | Value At Risk | -7.65 | Potential Upside | 7.66 | Standard Deviation | 4.21 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Acrivon Therapeutics, historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Acrivon Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Acrivon Therapeutics,, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Acrivon Therapeutics, Common back and forth among themselves.
| Shares | Dafna Capital Management Llc | 2024-09-30 | 112.4 K | Northern Trust Corp | 2024-09-30 | 105.4 K | Ubs O'connor Llc | 2024-09-30 | 79.2 K | Bridgeway Capital Management, Llc | 2024-09-30 | 77 K | Baker Bros Advisors Lp | 2024-09-30 | 52.9 K | Renaissance Technologies Corp | 2024-09-30 | 45.9 K | Exchange Traded Concepts, Llc | 2024-06-30 | 42.9 K | Springbok Capital Management, Llc | 2024-09-30 | 37.7 K | Bank Of New York Mellon Corp | 2024-06-30 | 36.6 K | Ra Capital Management, Llc | 2024-09-30 | 8.3 M | Perceptive Advisors Llc | 2024-09-30 | 5.4 M |
Acrivon Therapeutics, Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Acrivon Therapeutics, or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Acrivon Therapeutics,'s price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Acrivon stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.43 | |
β | Beta against Dow Jones | 1.76 | |
σ | Overall volatility | 4.15 | |
Ir | Information ratio | -0.08 |
Acrivon Therapeutics, Volatility Alert
Acrivon Therapeutics, Common exhibits very low volatility with skewness of -0.23 and kurtosis of 1.64. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Acrivon Therapeutics,'s stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Acrivon Therapeutics,'s stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Acrivon Therapeutics, Fundamentals Vs Peers
Comparing Acrivon Therapeutics,'s fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Acrivon Therapeutics,'s direct or indirect competition across all of the common fundamentals between Acrivon Therapeutics, and the related equities. This way, we can detect undervalued stocks with similar characteristics as Acrivon Therapeutics, or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Acrivon Therapeutics,'s fundamental indicators could also be used in its relative valuation, which is a method of valuing Acrivon Therapeutics, by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Acrivon Therapeutics, to competition |
| Fundamentals | Acrivon Therapeutics, | Peer Average |
| Return On Equity | -0.38 | -0.31 |
| Return On Asset | -0.24 | -0.14 |
| Current Valuation | 50.7 M | 16.62 B |
| Shares Outstanding | 31.14 M | 571.82 M |
| Shares Owned By Insiders | 22.38 % | 10.09 % |
| Shares Owned By Institutions | 75.97 % | 39.21 % |
| Number Of Shares Shorted | 1.11 M | 4.71 M |
| Price To Book | 1.19 X | 9.51 X |
| EBITDA | (59.85 M) | 3.9 B |
| Net Income | (60.39 M) | 570.98 M |
| Total Debt | 4.64 M | 5.32 B |
| Book Value Per Share | 5.38 X | 1.93 K |
| Cash Flow From Operations | (42.64 M) | 971.22 M |
| Short Ratio | 15.38 X | 4.00 X |
| Earnings Per Share | (2.66) X | 3.12 X |
| Target Price | 21.56 | |
| Number Of Employees | 58 | 18.84 K |
| Market Capitalization | 234.14 M | 19.03 B |
| Total Asset | 138.26 M | 29.47 B |
| Retained Earnings | (116.42 M) | 9.33 B |
| Working Capital | 116.39 M | 1.48 B |
| Net Asset | 138.26 M |
Note: Disposition of 19910 shares by Blume-jensen Peter of Acrivon Therapeutics, at 6.44 subject to Rule 16b-3 [view details]
Acrivon Therapeutics, Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Acrivon . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Acrivon Therapeutics, Buy or Sell Advice
When is the right time to buy or sell Acrivon Therapeutics, Common? Buying financial instruments such as Acrivon Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Acrivon Therapeutics, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Impulse Thematic Idea Now
Impulse
Large corporations operating in retail, broadcasting, energy, airlines and telecom sectors. The Impulse theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Impulse Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.